## CLX: Clorox Company (The) - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_10 -0.9% below STRENGTH zone (3.0-6.0%); PEG 3.44 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($100.89)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 2, Bearish: 0)

**1. Korea Investment CORP Grows Stake in The Clorox Company $CLX**
- Source: MarketBeat | 20251202T110417 | Neutral | Relevance: 99%
- Korea Investment CORP significantly increased its stake in The Clorox Company by 324.7% in Q2 2025, now owning 117,570 shares valued at approximately $14.12 million. Despite this increased institutional interest, analysts have recently issued "Reduce" ratings with an average price target of $125.69, following mixed Q3 results where EPS beat estimates but revenue declined. The company also declared a quarterly dividend of $1.24 per share.

**2. Clorox: A Dividend Champion Facing Headwinds, But Still A Buy (NYSE:CLX)**
- Source: Seeking Alpha | 20251202T093900 | Bullish | Relevance: 99%
- Clorox is positioned as a market leader with a 48-year dividend growth streak and a nearly 5% yield. Despite recent setbacks like revenue declines due to an ERP transition, cyberattack, and inflation, the company's IGNITE plan aims for 3-5% sales growth and improved margins. With acceptable dividend safety metrics and an undervaluation at ~$108/share compared to a fair value of $119.80, Clorox is recommended as a buy for dividend growth portfolios.

**3. BLI Banque de Luxembourg Investments Sells 10,500 Shares of The Clorox Company $CLX**
- Source: MarketBeat | 20251130T083233 | Neutral | Relevance: 98%
- BLI Banque de Luxembourg Investments reduced its stake in The Clorox Company by 13.9% in the second quarter, selling 10,500 shares. Several other institutional investors also adjusted their positions in CLX, while director Pierre R. Breber purchased 4,000 shares and COO Eric H. Reynolds sold over 15,000 shares. The article also provides a financial overview of Clorox, its recent earnings, dividend announcement, and current analyst ratings.

**4. Clorox (NYSE:CLX) Upgraded to Hold at Zacks Research**
- Source: MarketBeat | 20251130T123216 | Neutral | Relevance: 98%
- Zacks Research upgraded Clorox (NYSE:CLX) from a "strong sell" to a "hold" rating, despite other analysts trimming price targets and the MarketBeat consensus remaining "Reduce" with a $125.69 target. The company beat quarterly EPS estimates ($0.85 vs. $0.78) but revenue fell 18.9% year-over-year, leading to FY2026 guidance ($5.95â€“$6.30 EPS) below analyst expectations. Insider activity was mixed, with the COO selling shares and a director purchasing shares.

**5. Hsbc Holdings PLC Sells 70,825 Shares of The Clorox Company $CLX**
- Source: MarketBeat | 20251130T114626 | Neutral | Relevance: 97%
- Hsbc Holdings PLC reduced its stake in The Clorox Company by 6.5% during Q2 2025, selling 70,825 shares and retaining 1,014,836 shares valued at approximately $121.6 million. The article also details other institutional investor activity, insider transactions including purchases by Director Pierre R. Breber and sales by COO Eric H. Reynolds, and recent analyst ratings that have resulted in a consensus "Reduce" rating with an average price target of $125.69. Clorox reported quarterly earnings of $0.85 EPS, beating estimates, and declared a quarterly dividend of $1.24 per share.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 21 ($20.47M) |
| Sells | 4 ($1.06M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.9% (-0.7%)
- Blackrock Inc.: 8.5% (-1.2%)
- State Street Corpora: 6.9% (+3.5%)
- Invesco Ltd.: 3.3% (+23.1%)
- Morgan Stanley: 2.6% (+18.3%)

### Key Risks

1. Valuation stretched: PEG 3.4x requires aggressive growth execution.
2. Long-term trend broken: trading 17.3% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.44 signals overvaluation risk, limited margin of safety. Quality metrics strong (ROE 44%, ROA 12%). Insider buying signal ($20.5M), management confidence. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $12.5B |
| Beta | 0.57 |
| 52W Range | $98.20 - $169.15 |
| Short Interest | 6.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.44 |
| Forward P/E | 15.6 |
| Current P/E | 17.7 |
| YoY Growth | 12.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.5% to -0.9% (-3.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.9pp (needs >3.0% for momentum thesis). Below SMA200 (0.83x), long-term trend not supportive. MACD histogram positive (1.00), confirming momentum. RSI neutral at 45.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.91% (CS: 56) | Neutral |
| RSI_14 | 44.6 | Neutral |
| MACD Histogram | 1.00 | Bullish |
| vs SMA20 | 1.009x | Above |
| vs SMA50 | 0.935x | Below |
| vs SMA200 | 0.827x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $105.89
- **Stop Loss:** $100.89 (4.7% risk)
- **Target:** $110.89 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 200
- **Position Value:** $21,178.00
- **Portfolio %:** 21.18%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-03 (Est: $1.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.78 | $0.85 | +9.2% |
| 2025Q2 | $2.21 | $2.87 | +29.8% |
| 2025Q1 | $1.56 | $1.45 | -6.9% |
| 2024Q4 | $1.40 | $1.55 | +10.7% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*